Current evidence for aripiprazole as augmentation therapy in major depressive disorder

References

• Kessler RC, Berglund P, Demler O et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA289, 3095–3105 (2003).
   PubMed Web of Science ®Google Scholar
• Hasin DS, Goodwin RD, Stinson FS, Grant BF. Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch. Gen. Psychiatr.62, 1097–1106 (2005).
   PubMed Web of Science ®Google Scholar
• Ustün TB, Ayuso-Mateos JL, Chatterji S, Mathers C, Murray CJ. Global burden of depressive disorders in the year 2000. Br. J. Psychiatry184, 386–392 (2004).
   PubMed Web of Science ®Google Scholar
• Fava M, Davidson, KG. Definition and epidemiology of treatment-resistant depression. Psychiatr. Clin. North Am.19, 179–200 (1996).
   PubMed Web of Science ®Google Scholar
• Frank E, Karp J, Rush AJ. Efficacy of treatments for major depression. Psychopharmacol. Bull.29, 457–494 (1993).
   PubMedGoogle Scholar
• Keller MB, Shapiro RW, Lavori PW, Wolfe N. Recovery in major depressive disorder: analysis with the life table and regression models. Arch. Gen. Psychiatry39, 905–910 (1982).
   PubMed Web of Science ®Google Scholar
• Scott J. Chronic depression. Br. J. Psychiatry153, 287–297 (1988).
   PubMed Web of Science ®Google Scholar
• Thase ME. What role do atypical antipsychotic drugs have in treatment-resistant depression? J. Clin. Psychiatry63, 95–103 (2002).
   PubMed Web of Science ®Google Scholar
• Judd LL, Akiskal HS, Maser JD et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J. Affect. Disord.50, 97–108 (1998).
   PubMed Web of Science ®Google Scholar
• Van Londen L, Molenaar RP, Goekoop JG, Zwinderman AH, Rooijmans HG. Three to 5-year prospective follow-up of outcome in major depression. Psychol. Med.28, 731–735 (1998).
   PubMed Web of Science ®Google Scholar
• Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A. Residual symptoms after partial remission: an important outcome in depression. Psychol. Med.25, 1171–1180 (1995).
   PubMed Web of Science ®Google Scholar
• Thase ME, Simons AD, McGeary J et al. Relapse after cognitive behavior therapy of depression: potential implications for longer courses of treatment. Am. J. Psychiatry149, 1046–1052 (1992).
   PubMed Web of Science ®Google Scholar
• Miller IW, Keitner GI, Schatzberg AF et al. The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J. Clin. Psychiatry59, 608–619 (1998).
   PubMed Web of Science ®Google Scholar
• Judd LL, Paulus MJ, Schettler PJ et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am. J. Psychiatry157, 1501–1504 (2000).
   PubMed Web of Science ®Google Scholar
• Thase ME, Evaluating antidepressant therapies: remission as the optimal outcome. J. Clin. Psychiatry64(Suppl. 13), 18–25 (2003).
   PubMedGoogle Scholar
• Zajecka JM. Treating depression to remission. J. Clin. Psychiatry64(Suppl. 15), 7–12 (2003).
   PubMedGoogle Scholar
• Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry163, 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry163, 1905–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Fava M, Wisniewski SR et al. Medication augmentation after the failure of SSRIs for depression. N. Engl. J. Med.354, 1243–1252 (2006).
   PubMed Web of Science ®Google Scholar
• Lam RW, Hossie H, Solomons K, Yatham LN. Citalopram and bupropion-SR: combining versus switching in patients with treatment-resistant depression. J. Clin. Psychiatry65, 337–340 (2004).
   PubMed Web of Science ®Google Scholar
• Dé Montigny C, Grunberg F, Mayer A, Deschenes JP. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br. J. Psychiatry138, 252–256 (1981).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am. J. Psychiatry163, 1519–1530 (2006).
   PubMed Web of Science ®Google Scholar
• Bauer M, Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J. Clin. Psychopharmacol.19, 427–434 (1999).
   PubMed Web of Science ®Google Scholar
• Bauer M, Bschor T, Kunz D. Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression. Am. J. Psychiatry157, 1429–1435 (2000).
   PubMed Web of Science ®Google Scholar
• Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch. Gen. Psychiatry53, 842–848 (1996).
   PubMed Web of Science ®Google Scholar
• Altshuler LL, Bauer M, Frye MA et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am. J. Psychiatry158, 1617–1622 (2001).
   PubMed Web of Science ®Google Scholar
• Barowsky J, Schwartz TL. An evidence-based approach to augmentation and combination strategies for treatment-resistant depression. Psychiatry3, 42–61 (2006).
   PubMedGoogle Scholar
• Carvalho AF, Cavalcante JL, Castelo MS, Lima MCO. Augmentation strategies for treatment-resistant depression: a literature review. J. Clin. Pharm. Ther.32(5), 415–428 (2007).
   PubMed Web of Science ®Google Scholar
• Shelton RC, Tollefson GD, Tohen M et al. A novel augmentation strategy for treating resistant major depression. Am. J. Psychiatry158, 131–134 (2001).
   PubMed Web of Science ®Google Scholar
• Shelton RC, Williamson DJ, Corya SA et al. Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance. J. Clin. Psychiatry66, 1289–1297 (2005).
   PubMed Web of Science ®Google Scholar
• Thase ME, Corya SA, Osuntokun O et al. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment resistant major depressive disorder. J. Clin. Psychiatry68, 224–236 (2007).
   PubMed Web of Science ®Google Scholar
• Corya SA, Williamson D, Sanger TM, Briggs SD, Case M, Tollefson G. A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression. Depress. Anxiety23, 364–372 (2006).
   PubMed Web of Science ®Google Scholar
• McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress. Anxiety24, 487–494 (2007).
   PubMed Web of Science ®Google Scholar
• Dorée JP, Des Rosiers J, Lew V et al. Quetiapine augmentation of treatment-resistant depression: a comparison with lithium. Curr. Med. Res. Opin.23, 333–341 (2007).
   PubMed Web of Science ®Google Scholar
• Ostroff RB, Nelson JC. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression. J. Clin. Psychiatry60, 256–259 (1999).
   PubMed Web of Science ®Google Scholar
• Mahmoud RA, Pandina GJ, Turkoz I et al. Risperidone for treatment-refractory major depressive disorder: a randomized trial. Ann. Intern. Med.147, 593–602 (2007).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Nierenberg AA et al. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J. Clin. Psychiatry65, 217–221 (2004).
   PubMed Web of Science ®Google Scholar
• Abilify®, prescribing information. Bristol-Myers Squibb Company, Otsuka America Pharmaceutical, Inc. USA (2007).
   Google Scholar
• Shapiro DA, Renock S, Arrington E et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology28, 1400–1411 (2003).
   PubMed Web of Science ®Google Scholar
• Zangen A, Nakash R, Overstreet DH, Yadid G. Association between depressive behavior and absence of serotonin-dopamine interaction in the nucleus aaccumbens. Psychopharmacol.155, 434–439 (2001).
   Web of Science ®Google Scholar
• Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur. J. Pharmacol.441, 137–140 (2002).
   PubMed Web of Science ®Google Scholar
• Glennon RA, Dukat M. Serotonin receptor subtypes. In: Pharmacology: The Fourth Generation Of Progress. Bloom FE, Kupfer DJ (Eds). Raven Press, NY, (1995).
   Google Scholar
• Scott JA, Crews FT. Down-regulation of serotonin 2, but not of b-adrenergic receptors during chronic treatment with amitriptyline is independent of stimulation of serotonin 2 and b-adrenergic receptors. Neuropharmacology25, 1301–1306 (1986).
   PubMed Web of Science ®Google Scholar
• Chew ML, Mulsant BH, Pollock BG, Lehman ME et al. A model of anticholinergic activity of atypical antipsychotic medications. Schizophr. Res.88, 63–72 (2006).
   PubMed Web of Science ®Google Scholar
• Fava M. Augmentation and combination strategies in treatment-resistant depression. J. Clin. Psychiatry62(Suppl. 18), 4–11 (2001).
   PubMed Web of Science ®Google Scholar
• Blier P, Szabo ST. Potential mechanisms of action of atypical antipsychotic medications in treatment-resistant depression and anxiety. J. Clin. Psychiatry66(Suppl. 8), 30–40 (2005).
   PubMed Web of Science ®Google Scholar
• Bortolozzi A, Diaz-Mataix L, Toth M, Celada P, Artigas F. In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain. Psychopharmacology191, 745–758 (2007).
   PubMed Web of Science ®Google Scholar
• Pae C, Serretti A, Patkar AA, Masand PS. Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence. CNS Drugs22(5), 367–388 (2008).
   PubMed Web of Science ®Google Scholar
• Lehto SM, Kuikka J, Tolmunen T et al. Temporal cortex dopamine D2/3 receptor binding in major depression. Psychiatry Clin. Neurosci.62, 345–348 (2008).
   PubMed Web of Science ®Google Scholar
• Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J. Affect. Disord.86, 99–104 (2005).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen TJ, Kinrys G et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant major depressive disorder. J. Clin. Psychiatry66, 1326–1330 (2005).
   PubMed Web of Science ®Google Scholar
• Pae C, Patkar AA, Jun T et al. Aripiprazole augmentation for treatment of patients with inadequate antidepressants response. Depress. Anxiety24, 522–526 (2007).
   PubMed Web of Science ®Google Scholar
• Simon JS and Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J. Clin. Psychiatry66, 1216–1220 (2005).
   PubMed Web of Science ®Google Scholar
• Rutherford B, Sneed J, Miyazaki M et al. An open trial of aripiprazole augmentation for SSRI non-remitters with late-life depression. Int. J. Geriatr. Psychiatry22, 986–991 (2007).
   PubMed Web of Science ®Google Scholar
• Patkar AA, Peindl K, Mago R et al. An open-label, rater-blinded, augmentation study of aripiprazole in treatment-resistant depression. Prim. Care Companion J. Clin. Psychiatry8, 82–87 (2006).
   PubMedGoogle Scholar
• Hellerstein DJ, Batchelder S, Hyler S et al. Aripiprazole as an adjunctive treatment for refractory unipolar depression. Prog. Neuropsychopharmacol. Biol. Psychiatry32, 744–750 (2008).
   PubMed Web of Science ®Google Scholar
• Schule C, Baghai TC, Eser D et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J. Biol. Psychiatry8, 112–122 (2007).
   PubMed Web of Science ®Google Scholar
• Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann. Clin. Psychiatry16, 189–194 (2004).
   PubMedGoogle Scholar
• Worthington JJ 3rd, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int. Clin. Psychopharmacol.20, 9–11 (2005).
   PubMed Web of Science ®Google Scholar
• Berman RM, Marcus RN, Swanink R et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychiatry68, 843–853 (2007).
   PubMed Web of Science ®Google Scholar
• Marcus RN, McQuade RD, Carson WH et al. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. J. Clin. Psychopharmacol.28, 156–165 (2008).
   PubMed Web of Science ®Google Scholar
• Thase ME, Jonas A, Khan A et al. Aripiprazole monotherapy in non-psychotic bipolar I depression. Results of 2 randomized, placebo-controlled studies. J. Clin. Psychopharmacol.28, 12–20 (2008).
   Google Scholar
• Miller DD, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J. Clin. Psychiatry68, 1901–1906 (2007).
   PubMed Web of Science ®Google Scholar